

## PROGRAM

Thursday, May 29<sup>th</sup>, 2008

8:00-17:00 Registration of Participants

Thursday, May 29, 2008: Plenary Room

### SELECTED PAPERS

Chairman:

*A. Belchev (Sofia, Bulgaria)*

- 9:00-9:30 **C. Rupnik** (*Logatec, Slovenia, EU*)  
Why our patients needed extra take home doses?
- 9:30-10:00 **O. Aizberg** (*Minsk, Belarus*)  
First results of Belarus pilot methadone treatment project
- 10:00-10:30 **M.C. Pieri** (*Bologna, Italy, EU*)  
Comprehensive treatment of HCV+ heroin addicts in the SerT of Bologna, Italy
- 10:30-11:00 **L. Somaini** (*Biella, Italy, EU*)  
Opioid therapy and restoration of immune function in heroin addict patients

Thursday, May 29, 2008: Plenary Room

### THE USE OF GHB IN THE MEDICALLY ASSISTED REHABILITATION FOR ALCOHOLIC PATIENTS

Chairman:

*I. Maremmani (Pisa, Italy, EU)*

- 11:00-11:30 **I. Maremmani** (*Pisa, Italy, EU*)  
Is GHB for alcohol like methadone for heroin?
- 11:30-12:00 **F. Caputo** (*Ferrara, Italy, EU*)  
Clinical use of gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence

*Sponsored by Laboratorio Farmaceutico CT Sanremo*

Thursday, May 29, 2008: Plenary Room

### SPECIAL EVENT.

#### METHADONE TREATMENT: FORTY YEARS OF ADVOCACY

Chairmen:

*R. Newman (New York, NY, USA)*  
*R. Nardini (Pietrasanta, Italy, EU)*

12:00-14:00 Participants:

**R. Donski** (*Sofia, Bulgaria, EU*)  
**M. F. Fonseca** (*Barcelona, Spain, EU*)  
**R. Gerlach** (*Munster, Germany, EU*)  
**V. Mendelevich** (*Kazan, Russia*)  
**T. Santini** (*Zagreb, Croatia*)

This panel will be comprised of experienced participants in addiction treatment services, as patients, advocates or providers, in Russia, Croatia, Germany, Spain and Bulgaria. After brief introductions, the moderators (from USA and Italy) will pose questions to the panelists asking them to comment on a variety of topics: difficulties faced in introducing and/or maintaining treatment services; factors associated with success - and failure - of treatment efforts; how to measure effectiveness of treatment.

*In collaboration with International Center for Advancement of Addiction Treatment, Baron Edmond de Rothschild Chemical Dependency Institute of Beth Israel Medical Center*

Thursday, May 29, 2008: Plenary Room

### CME PRE-CONFERENCE WORKSHOP. BUPRENORPHINE EDUCATIONAL MEETING

Chairmen:

*I. Maremmani (Pisa, Italy)*  
*A. Kantchelov (Sofia, Bulgaria)*

- 14:00-14:25 **S. Walsh** (*Lexington, KY, USA*)  
The pharmacology of buprenorphine and the buprenorphine-naloxone combination
- 14:25-14:50 **N. Lintzeris** (*Melbourne, Australia*)  
Understanding buprenorphine - dose titrations and protocols: best practice
- 14:50-15:15 **W. Ling** (*Los Angeles, CA, USA*)  
Chronic pain, analgesic addiction and pharmacotherapy
- 15:15-15:40 **S. Comer** (*New York, NY, USA*)  
Self-administration of IV buprenorphine compared to buprenorphine/naloxone in buprenorphine-maintained individuals
- 15:40-16:05 **J. Myles** (*London, UK, EU*)  
Managing opioid dependency in the context of affective disorder
- 16:05-16:30 **S. Walcher** (*Munich, Germany, EU*)  
HCV and HIV in an opioid-dependent patient
- 16:30-16:55 **I. Maremmani** (*Pisa, Italy*)  
Quality of Life. A comparison between buprenorphine and methadone treated patients

*Sponsored by Schering-Plough*

Thursday, May 29, 2008: Plenary Room

### OPENING LECTURES

Chairmen:

*I. Maremmanni (Pisa, Italy, EU)*  
*M. Reisinger (Bruxelles, Belgium, EU)*

- 17:00-17:30 **I. Maremmanni** (Pisa, Italy, EU) &  
**A. Kantchelov** (Sofia, Bulgaria, EU)  
Welcome addresses and opening remarks
- 17:30-18:00 **M. Parrino** (New York, NY, USA)  
Coordinating methadone treatment providers and  
policy makers: Lessons learned over 30 years
- 18:00-19:00 **P. Quigley** (Dublin, Ireland, EU)  
What kind of science is addiction science?
- 19:00-20:00 **A. Uchtenhagen** (Zurich, Switzerland)  
Treatment of addicts on Court order: Results  
from a European study on quasi-compulsory  
treatment

Thursday, May 29, 2008: Plenary Room

### 20:30-21:30 WELCOME COCKTAIL AND EUROPAD CHIMERA AWARD 2008

Chairmen:

*I. Maremmanni (Pisa, Italy, EU)*  
*M. Reisinger (Bruxelles, Belgium, EU)*

To be awarded:

Gabriele Fischer (Vienna, Austria, EU)  
Andrej Kastelic (Lubiana, Slovenia, EU)  
Didier Touzeau (Paris, France, EU)

Former recipients

Arezzo, Italy, 2000	Olof Blix (Sweden)
Oslo, Norway, 2002	Marc Auriacombe (France)
	Mercedes Lovrecic (Slovenia)
	Lubomir Okruhlica (Slovak Republic)
Paris, France, 2004	Jean-Jacques Deglon (France)
	Alexander Kantchelov (Bulgaria)
	Icro Maremmanni (Italy)
	Pier Paolo Pani (Italy)
	Marc Reisinger (Belgium)
	Alessandro Tagliamonte (Italy)
Bratislava, Slovak Republic, 2006	Gilberto Gerra (Italy)
	Ante Ivancic (Croatia)
	Marta Torrens (Spain)
Pietrasanta, Italy, 2007	Joyce Lowinson (USA)

End of session

Friday, May 30<sup>th</sup>, 2008

Friday, May 30, 2008: Plenary Room

### SOUTH EASTERN EUROPEAN - ADRIATIC ADDICTION TREATMENT NETWORK

Chairman:

*A. Kastelic (Lubiana, Slovenia, EU)*

8:30-9:30 Organizing meeting

Friday, May 30, 2008: Plenary Room

### MAIN LECTURE

Chairman:

*M. Reisinger (Bruxelles, Belgium, EU)*

9:30-10:30 **J. Bell** (Sydney-London, Australia-UK, EU)  
Mortality in patients treated with methadone and  
buprenorphine

10:30-11:00 Break

Friday, May 30, 2008: Sofia 1 Room

### SYMPOSIUM 1

#### HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS

Chairman:

*I. Maremmanni (Pisa, Italy, EU)*

- 11:00-11:25 **B. Nordstrand** (Trondheim, Norway)  
Clinical experience with buprenorphine in  
Maintenance Treatment in Central Norway
- 11:25-11:50 **L. Okruhlica** (Bratislava, Slovak Republic, EU)  
Self-medication of psychoactive substances -  
different perspectives
- 11:50-12:15 **G. Gerra** (UNODC)  
Long-acting opioid-agonists in the treatment of  
heroin addiction: why we should not call them  
"substitution".
- 12:15-12:40 **M. Stenbacka** (Stockholm, Sweden, EU)  
Unintentional and intentional injuries due to opiate  
abuse
- 12:40-13:05 **A. Kastelic** (Lubiana, Slovenia, EU)  
Slow-release morphine (SROM)/methadone  
treatment comparison in Slovenia
- 13:05-13:30 **M. Reisinger** (Bruxelles, Belgium, EU)  
How to end an opiate agonist treatment?

Friday, May 30, 2008: Kyoto Salon

**SYMPOSIUM 2**  
**ALCOHOL DEPENDENCE**  
**IN HEROIN ADDICTS**

*Chairman:*  
*M. Pacini (Pisa, Italy, EU)*

- 11:00-11:30 **M. Backmund** (Munich, Germany, EU)  
Alcohol craving in heroin addicts: the role of agonist dose and medication choice
- 11:30-12:00 **M. Ceccanti** (Rome, Italy, EU)  
Alcoholics with a history of heroin consumption: clinical features and chronology of substance abuse
- 12:00-12:30 **A. Ulmer** (Stuttgart, Germany, EU)  
Opiate maintenance for the treatment of alcohol addiction
- 12:30-13:00 **M. Pacini** (Pisa, Italy, EU)  
Temperamental and psychiatric diagnosis in alcohol-heroin polyabusers
- 13:00-13:30 **M. Shinderman** (Chicago, IL, USA)  
Treating alcohol abuse as an opiate metabolism disorder: from antagonists to agonists.

Friday, May 30, 2008: Sofia 2 Room

**SYMPOSIUM 3**  
**NEW APPROACHES IN THE TREATMENT OF OPIOID**  
**DEPENDENCY DURING THE PREGNANCY**

*Chairman:*  
*L. Finnegan (Avalon, NJ, USA)*

- 11:00-11:30 **L. Finnegan** (Avalon, NJ, USA)  
The challenges of methadone pharmacotherapy in the treatment of pregnant opioid dependent women
- 11:30-12:00 **H. Jones** (Baltimore, MD, USA)  
Scientific evidence and practical experience in the decision to decrease dosage of methadone during pregnancy
- 12:00-12:30 **G. Fischer** (Vienna, Austria, EU)  
Scientific and practical recommendations for the use of buprenorphine in opioid dependent pregnant women
- 12:30-13:00 **M. Olofsson** (Copenhagen, Denmark, EU)  
Comprehensive treatment for the pregnant opioid dependent pregnant women—the traditional approaches and the new
- 13:00-13:30 **G. Welle-Strand** (Oslo, Norway)  
Norwegian experience: pregnancies and follow-up of the families in medication assisted treatment

13:30-14:30 Break

Friday, May 30, 2008: Sofia 1 Room

**SYMPOSIUM 4**  
**ADDICTION, OPIOID REPLACEMENT AND**  
**ANTIVIRAL TREATMENT: OPTION OR DUTY?**

*Chairman:*  
*S. Walcher (Munich, Germany, EU)*

- 14:30-15:00 **S. Walcher** (Munich, Germany, EU)  
Treatment of HCV in opioid agonist treatment: why it's not just an option
- 15:00-15:30 **M. Schäfer** (Essen, Germany, EU)  
Neurocognitive and psychiatric impacts of hepatitis C and IfN/Riba-treatment
- 15:30-16:00 **S. Rossol** (Frankfurt am Main, Germany, EU)  
HIV and HCV treatment in addiction: quality of life and economy
- 16:00-16:30 **V. Rehak** (Prague, Czech Republic)  
Successful treatment of hepatitis C in addicted patients

Friday, May 30, 2008: Kyoto Salon

**SYMPOSIUM 5**  
**PSYCHIATRIC COMORBIDITY OF HEROIN ADDICTS**

*Chairman:*  
*P.P. Pani (Cagliari, Italy, EU)*

- 14:30-15:00 **O. Blix** (Jonkoping, Sweden, EU)  
Treatment of opioid dependence and ADHD/ADD with methadone
- 15:00-15:30 **M. Lovrecic** (Lubiana, Slovenia, EU)  
Psychiatric comorbidity of Slovenian heroin addicts
- 15:30-16:00 **G. Perugi** (Pisa, Italy, EU)  
Heroin addiction and bipolarity
- 16:00-16:30 **P.P. Pani** (Cagliari, Italy, EU)  
Addiction: Orphan of psychopathology
- 16:30-17:00 **I. Maremmani** (Pisa, Italy, EU)  
Psychopathological dimensions of heroin addicts at treatment entry

Friday, May 30, 2008: Sofia 2 Room

### SYMPOSIUM 6

#### BUPRENORPHINE: PRACTICE AND PERSPECTIVE

Chairman:

*D. Touzeau (Paris, France, EU)*

*L. Patricio (Lisbon, Portugal, EU)*

- 14:30-14:55 **P. Courty** (*Clermont-Ferrand, France, EU*)  
Use and abuse of high dosing buprenorphine obtained without prescription: A French survey
- 14:55-15:20 **P. Galland** (*Beziers, France, EU*)  
Preference for buprenorphine/naloxone (Suboxone®) and buprenorphine (Subutex®) among patients receiving buprenorphine maintenance therapy in France: A prospective, multicenter study
- 15:20-15:45 **F. Pinto** (*Horta, Portugal, EU*)  
Changing Subutex to Suboxone – the experience of an Azorean Island
- 15:45-16:10 **H. Alho** (*Helsinki, Finland, EU*)  
Four year clinical experience of the buprenorphine-naloxone product in Finland
- 16:10-16:35 **S. Ballantyne** (*Queensland, Australia*)  
Observations on the prescription and diversion of Opioid Replacement Therapies after the introduction of suboxone: A third option for opioid pharmacotherapy
- 16:35-17:00 **B. Larance** (*Sidney, Australia*)  
The diversion and injection of opioid treatment (OT) following the introduction of buprenorphine-naloxone: Preliminary findings from surveillance studies in Australia

17:00-17:30 Break

Friday, May 30, 2008: Kyoto Salon

### SYMPOSIUM 7

#### PSYCHOTHERAPIES FOR PATIENTS TREATED WITH OPIOID AGONISTS

Chairman:

*A. Kantchelov (Sofia, Bulgaria, EU)*

- 17:30-18:00 **E. Bignamini** (*Torino, Italy, EU*)  
Psychotherapeutic management of heroin addicted patients: psychopathological, relational and organizing aspects
- 18:00-18:30 **R. Bes** (*Amsterdam, The Netherlands, EU*)  
Motivational interviewing: a heroin lifestyle agonist
- 18:30-19:00 **A. Belchev** (*Sofia, Bulgaria, EU*)  
Cognitive restructuring in methadone-assisted therapy
- 19:00-19:30 **B. Gacic** (*Belgrade, Serbia*)  
Systemic family therapy for heroin addiction

- 19:30-20:00 **O. Todorov** (*Sofia, Bulgaria, EU*)  
Psychotherapeutic experience with methadone maintained patients

Friday, May 30, 2008: Sofia 1 Room

### SYMPOSIUM 8

#### HEALTH RISKS IN OPIOID MAINTENANCE. BUPRENORPHINE, METHADONE AND OTHER AGONISTS IN COMPARISON

Chairman:

*H. Waal (Oslo, Norway)*

- 17:30-18:00 **H. Waal** (*Oslo, Norway*)  
What are the concerns?
- 18:00-18:30 **J. Bell** (*Sydney-London, Australia-UK, EU*)  
Morbidity associated with methadone and buprenorphine treatment
- 18:30-19:00 **M. Auriacombe** (*Bordeaux, France, EU*)  
Mortality and morbidity data in France. Methadone and buprenorphine in comparison. An example of the integration evidence-based medical management, safety driven concerns and a public health perspective?
- 19:00-19:30 **M. U. Pedersen** (*Aarhus, Denmark, EU*)  
What are the clinical significance of personality dimensions for opioid maintenance therapy? Findings in a prospective study based on the five factor model
- 19:30-20:00 **J. P Bernard** (*Oslo, Norway*)  
Methadone related deaths in Norway

Friday, May 30, 2008: Sofia 2 Room

### SYMPOSIUM 9

#### OPIOID AGONIST TREATMENT AND PAIN

Chairman:

*H. Joseph (New York, NY, USA)*

- 17:30-18:00 **H. Joseph** (*New York, NY, USA*)  
Opium: an ancient medication and the modern world
- 18:00-18:30 **J. Buttfield** (*North Adelaide, Australia*)  
Prescribing opioid and other medications to pain patients with and without histories of chemical dependency: the need for physician education
- 18:30-19:00 **A. Beeder** (*New York, NY, USA*)  
Pain management among chemically dependent patients on opioid maintenance
- 19:00-19:30 **F. Tennant** (*West Covina, CA, USA*)  
Pseudoaddiction: The illustrative case of Howard Hughes
- 19:30-20:00 **S. Burris** (*Philadelphia, PA, USA*)  
Policy barriers to opioid agonist treatment - and what to do about them

END OF SESSION

## Saturday, May 31<sup>th</sup>, 2008

*Saturday, May 31<sup>th</sup>, 2008: Kyoto Salon*

### MEET THE EXPERT

*Chairman:*

*M. Pacini (Pisa, Italy, EU)*

8:30-9:30 Methadone treatment: what's an adequate dosage?

*Saturday, May 31<sup>th</sup>, 2008: Plenary Room*

### WORLD FEDERATION FOR THE TREATMENT OF OPIOID DEPENDENCE

*Chairmen:*

*A. Kastelic (Ljubiana, Slovenia, EU)*

*I. Maremmani (Pisa, Italy, EU)*

*M. Parrino (New York, NY, USA)*

*M. Reisinger (Bruxelles, Belgium, EU)*

8:30-9:30 Organizing meeting

*Saturday, May 31<sup>th</sup>, 2008: Plenary Room*

### MAIN LECTURE

*Chairman:*

*P.P. Pani (Cagliari, Italy, EU)*

9:30-10:30 **N. Lintzeris** (*Melbourne, Australia*)  
The role of buprenorphine across the spectrum of harm reduction to comprehensive treatment interventions

10:30-11:00 **Break**

*Saturday, May 31<sup>th</sup>, 2008: Kyoto Salon*

### SYMPOSIUM 10

#### MAINTENANCE TREATMENT AND GPs.

#### VOICES OF EXPERIENCE

*Chairman:*

*A. Ivancic (Porec, Croatia)*

11:00-11:25 **H. Haltmayer** (*Vienna, Austria, EU*)  
Opioid treatment in Austria – a controversial issue once more!?

11:25-11:50 **P. Quigley** (*Dublin, Ireland, EU*)  
Addiction treatment and social inclusion in Dublin

11:50-12:15 **R. Ullman** (*Hamburg, Germany, EU*)  
Opiate maintenance treatment in primary health care in Germany

12:15-12:40 **N. Poole** (*Glasgow, Scotland, UK*)  
Primary care treatment of drug users in Scotland

12:40-13:05 **A. Ivancic** (*Porec, Croatia*)  
From methadone to buprenorphine or back to methadone - Croatian experience

13:05-13:30 **A. Michelazzi** (*Trieste, Italy, EU*)  
Methadone treatment in the General Practitioner Office in Trieste, Italy. Proven therapeutic efficacy and predictive factors in responding to treatment

*Saturday, May 31<sup>th</sup>, 2008: Sofia 1 Room*

### SYMPOSIUM 11

#### QUALITY OF LIFE AND AGONIST OPIOID TREATMENT

*Chairman:*

*M. Torrens (Barcelona, Spain, EU)*

11:00-11:30 **M. Torrens** (*Barcelona, Spain, EU*)  
Quality of Life as an Outcome Measure in Opioid Dependence Treatment

11:30-12:00 **A. Domingo-Salvany** (*Barcelona, Spain, EU*)  
Opioid Dependence and Quality of Life: Changes in the Heroin Epidemic

12:00-12:30 **I. Maremmani** (*Pisa, Italy, EU*)  
Improvement of Quality of Life in Heroin Addicts: Differences between Methadone and Buprenorphine Treatment

12:30-13:00 **R. Martín-Santos** (*Barcelona, Spain, EU*)  
Hepatitis C infection and Quality of Life in Opioid Dependence

13:00-13:30 **J. Teigland** (*Bergen, Norway*)  
Norwegian drug users seeking help from other Schengen countries

*Saturday, May 31<sup>th</sup>, 2008: Sofia 2 Room*

### SYMPOSIUM 12

#### DRUG TREATMENT IN EASTERN EUROPE.

#### RESEARCH FINDINGS AND SOCIAL BARRIERS

*Chairman:*

*S. Dvoryak (Kiev, Ukraine)*

11:00-11:25 **A. Kantchev** (*Sofia, Bulgaria, EU*)  
From harm reduction to methadone-assisted therapy: 12 years of Bulgarian experience

11:25-11:50 **S. Dvoryak** (*Kiev, Ukraine*)  
Comprehensive treatment for marginalized groups of population in Ukraine

11:50-12:15 **V. Mendelevich** (*Kazan, Russia*)  
Why Russian narcologists against substitution therapy?

12:15-12:40 **E. Subata** (*Vilnius, Lithuania, EU*)  
Process evaluation of opioid agonist therapy – the implications for service providers to improve the quality of services

12:40-13:05 **S. Koren** (*Moscow, Russia*)  
Administration of Nalbuphine to heroin addicts in Russia

13:05-13:30 **M. Majdová** (*Bratislava, Slovak Republic*)  
Treatment responses to Methamphetamine use in MMTP

13:30-15:00 **Break**

*Saturday, May 31th, 2008: Kyoto Salon*

**SPECIAL EVENT - AATOD FORUM  
MAJOR POLICY AND CLINICAL DEVELOPMENTS IN THE USE  
OF METHADONE AND BUPRENORPHINE TREATMENT IN THE  
UNITED STATES**

*Chairman:*

*M. Parrino (New York, NY, USA)*

15:00-17:00 Participants

**M. Parrino** (*New York, NY, USA*)

**B. Primm** (*New York, NY, USA*)

**K. Kaltenbach** (*Philadelphia, PA, USA*)

**I. Marion** (*New York, NY, USA*)

*Sponsored in part by a grant from Bendiner & Schlesinger, Inc. Medical Laboratories*

*Saturday, May 31th, 2008: Kyoto Salon*

**CLOSING CEREMONY AND WELCOME TO THE NEXT  
EUROPEAN EUROPAD CONFERENCE**

*Chairman:*

*M. Reisinger (Bruxelles, Belgium, EU)*

17:00-17:30 Closing remarks

*Saturday, May 31th, 2008: The Kantchelov Clinic*

**VISIT TO THE KANTCHELOV CLINIC**

18:00-19:00 Meeting patients in treatment

*Saturday, May 31th, 2008: The Kantchelov Clinic*

**SATELLITE MEETING  
WHAT IS AN ADEQUATE DOSE OF METHADONE?**

*Chairman:*

*I. Maremmanni (Pisa, Italy, EU)*

19:00-20:00 Participants:

**S. Dvoryak** (*Kiev, Ukraine*)

**M. Farrell** (*London, UK, EU*)

**M. Gossop** (*London, UK, EU*)

**L. Patricio** (*Lisbon, Portugal, EU*)

**M. Torrens** (*Barcelona, Spain, EU*)

**A. Ulmer** (*Stuttgart, Germany, EU*)

**S. Walcher** (*Munich, Germany, EU*)

*Sponsored by Molteni Farmaceutici*